Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Percentage-retracement levels are yet another technical indicator useful in defining short- and long-term price trends in a security or sector. Percentage retracement levels are based upon the ...

For active investors, the challenge is not typically finding a good stock or an entry point; it’s knowing where to get out. When a stock surges past its previous high, you enter what technical ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...